Prof. Dr. İrfan Çiçin

Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)

Gastric Cancer, 2022

DOI 10.1007/s10120-021-01271-9 PMID 34997449 10 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series

Breast Cancer Targets and Therapy, 2022

DOI 10.2147/bctt.s380754 PMID 36105268 12 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

Clinical Genitourinary Cancer, 2022

DOI 10.1016/j.clgc.2022.07.006 PMID 35970759 6 citations (Europe PMC) Source : OpenAlex

Relationship between prognostic nutritional index and neutrophil lymphocyte ratio with overall survival in patients with metastatic colorectal cancer receiving regorafenib

Journal of Cancer Research and Therapeutics, 2022

DOI 10.4103/jcrt.jcrt_1620_21 PMID 37470607 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Recurrent Delayed Immune-Related Pneumonitis After Immune-Checkpoint Inhibitor Therapy for Advanced Osteosarcoma

Immunotherapy, 2022

DOI 10.2217/imt-2021-0275 PMID 35152716 7 citations (Europe PMC) Source : OpenAlex

Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey

Future Oncology, 2022

DOI 10.2217/fon-2022-0455 PMID 36040321 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies

Cancers, 2022

DOI 10.3390/cancers14051168 PMID 35267477 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology, 2022

DOI 10.1200/jco.2022.40.16_suppl.9016 70 citations (OpenAlex) Source : OpenAlex

Clinical efficacy and safety of the BAT1706 (proposed bevacizumab biosimilar) compared with reference bevacizumab in patients with advanced nonsquamous NSCLC: A randomized, double-blind, phase III study.

Journal of Clinical Oncology, 2022

DOI 10.1200/jco.2022.40.16_suppl.9041 3 citations (OpenAlex) Source : OpenAlex

Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series

Research Square, 2022

DOI 10.21203/rs.3.rs-1447957/v1 Texte intégral en libre accèsSource : OpenAlex

Breast Cancer Subtypes And Prognosis: Answers To Subgroup Classification Questions, Identifying The Worst Subgroup In Our Single-Center Series

2022

DOI 10.32388/ub8v1e Texte intégral en libre accèsSource : OpenAlex

Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

Bursa Uludag University - AVESIS, 2022

Source : OpenAlex

Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients

Journal of Men s Health, 2021

DOI 10.31083/jomh.2021.041 5 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

The Lancet, 2021

DOI 10.1016/s0140-6736(21)00228-2 PMID 33581821 644 citations (Europe PMC) Source : OpenAlex

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer

JAMA Oncology, 2021

DOI 10.1001/jamaoncol.2021.3523 PMID 34473194 225 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Journal of Clinical Oncology, 2021

DOI 10.1200/jco.20.03579 PMID 33513313 204 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer

Clinical Lung Cancer, 2021

DOI 10.1016/j.cllc.2021.04.005 PMID 34034991 39 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade

British Journal of Cancer, 2021

DOI 10.1038/s41416-021-01532-5 PMID 34621044 27 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Prognostic nutritional index and its dynamics after curative treatment are independent prognostic factors on survival in non-metastatic nasopharyngeal carcinoma

Supportive Care in Cancer, 2021

DOI 10.1007/s00520-021-06627-6 PMID 34677649 14 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Investigation of the relationship between GSTM1 gene variations and serum trace elements, plasma malondialdehyde levels in patients with colorectal cancer

Molecular Biology Reports, 2021

DOI 10.1007/s11033-021-06694-2 PMID 34498162 9 citations (Europe PMC) Source : OpenAlex

Secondary Pneumothorax During Immunotherapy in two Patients with Metastatic Solid Tumors; a New Entity

Immunotherapy, 2021

DOI 10.2217/imt-2020-0233 PMID 33820440 7 citations (Europe PMC) Source : OpenAlex

Nivolumab in Metastatic Renal Cell Carcinoma: Results from the Turkish Oncology Group Kidney Cancer Consortium Database

Future Oncology, 2021

DOI 10.2217/fon-2021-0717 PMID 34726480 7 citations (Europe PMC) Source : OpenAlex

An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

European Journal of Breast Health, 2021

DOI 10.4274/ejbh.galenos.2021.2021-9-9 PMID 35059593 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?

PubMed, 2021

PMID 34761635 5 citations (Europe PMC) Source : OpenAlex

Prognostic Factors for Survival in Transverse Colon Cancers

Journal of Gastrointestinal Cancer, 2021

DOI 10.1007/s12029-021-00675-1 PMID 34302255 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Nasal hemangiopericytoma presenting with oncogenic osteomalasia: A case report and literature review

Current Problems in Cancer, 2021

DOI 10.1016/j.currproblcancer.2020.100704 PMID 33446319 1 citation (Europe PMC) Source : OpenAlex

Skeletal muscle loss during anti-epidermal growth factor receptor therapy is an independent prognostic factor on non-small cell lung cancer patients survival.

PubMed, 2021

PMID 34268945 2 citations (Europe PMC) Source : OpenAlex

Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma

Tumori Journal, 2021

DOI 10.1177/0300891621996448 PMID 33624577 2 citations (Europe PMC) Source : OpenAlex

Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.

PubMed, 2021

PMID 34565028 2 citations (Europe PMC) Source : OpenAlex

Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.

Journal of Clinical Oncology, 2021

DOI 10.1200/jco.2021.39.15_suppl.9085 9 citations (OpenAlex) Source : OpenAlex

Abstract CT179: Telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer

Cancer Research, 2021

DOI 10.1158/1538-7445.am2021-ct179 9 citations (OpenAlex) Source : OpenAlex

Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.

Journal of Clinical Oncology, 2021

DOI 10.1200/jco.2021.39.15_suppl.9038 3 citations (OpenAlex) Source : OpenAlex

Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.

Journal of Clinical Oncology, 2021

DOI 10.1200/jco.2021.39.15_suppl.9078 3 citations (OpenAlex) Source : OpenAlex

Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

Journal of Clinical Oncology, 2021

DOI 10.1200/jco.2021.39.6_suppl.321 1 citation (OpenAlex) Source : OpenAlex

Abstract OT-09-09: AMEERA-3, a phase 2 trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (her2−), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies

Cancer Research, 2021

DOI 10.1158/1538-7445.sabcs20-ot-09-09 Source : OpenAlex

Metastatic cutaneous melanoma epidemiological registry in Turkey: A preliminary evaluation of diagnosis and treatment approaches

Sakarya Üniversitesi Kurumsal Açık Akademik Arşivi, 2021

Source : OpenAlex

Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer.

Journal of Clinical Oncology, 2021

DOI 10.1200/jco.2021.39.15_suppl.e15561 Source : OpenAlex

The relation between tissue galectin-3 level and platinum resistance in neoadjuvant bladder cancer treatment.

PubMed, 2021

PMID 34268970 Source : OpenAlex

Distribution Data of Epidermal Growth Factor Receptor Mutations Detected by Next-Generation Sequencing Method in Non-Small Cell Lung Cancer

Journal of Oncological Sciences, 2021

DOI 10.37047/jos.2021-84407 Texte intégral en libre accèsSource : OpenAlex

Metastatic cutaneous melanoma epidemiological registry in Turkey: A preliminary evaluation of diagnosis and treatment approaches

Bursa Uludag University - AVESIS, 2021

Source : OpenAlex

AMEERA-3, a phase 2 trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (her2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies

Trakya University's Institutional Open Access System (Trakya University), 2021

Source : OpenAlex

Need for patient education and better physician-patient communication in melanoma patients: Behaviors and knowledge of melanoma patients

TURKDERM, 2021

DOI 10.4274/turkderm.galenos.2020.44538 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

PROGNOSTIC AND PREDICTIVE MARKERS OF FOLFIRI/AFLIBERCEPT IN PATIENTS WITH METASTATIC COLORECTAL CANCER (TOG STUDY)

AYBU AVESIS, 2020

Source : OpenAlex

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Lung Cancer, 2020

DOI 10.1016/j.lungcan.2020.07.022 PMID 32799090 30 citations (Europe PMC) Source : OpenAlex

Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.

Journal of Clinical Oncology, 2020

DOI 10.1200/jco.2020.38.15_suppl.e13055 Source : OpenAlex

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Journal of Clinical Oncology, 2020

DOI 10.1200/jco.20.02514 PMID 32954927 837 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology, 2020

DOI 10.1016/s1470-2045(20)30539-8 PMID 33285097 584 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

Journal of Thoracic Oncology, 2020

DOI 10.1016/j.jtho.2020.06.015 PMID 32599071 504 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study

ESMO Open, 2020

DOI 10.1136/esmoopen-2020-000698 PMID 32487542 30 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)

Journal of Oncology Pharmacy Practice, 2020

DOI 10.1177/1078155219900908 PMID 32054412 9 citations (Europe PMC) Source : OpenAlex